[(2-bromo-4,5-difluorobenzyl)oxy](tert-butyl)dimethylsilane | 1266727-98-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(2-bromo-4,5-difluorobenzyl)oxy](tert-butyl)dimethylsilane
• 英文别名: (2-bromo-4,5-difluorophenyl)methoxy-tert-butyl-dimethylsilane
• CAS: 1266727-98-3
• 化学式: C₁₃H₁₉BrF₂OSi
• 分子量: 337.28
• InChiKey: MGGYBQRARSLWGS-UHFFFAOYSA-N

物化性质

• 沸点：
  299.5±35.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.25
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(2-bromo-4,5-difluorobenzyl)oxy](tert-butyl)dimethylsilane 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 吡啶 、 盐酸羟胺 、 四丁基氟化铵 、 二异丁基氢化铝 、 sodium carbonate 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 25.0h， 生成 tert-butyl (1R,3'R)-5,6-difluoro-3'-[(E)-(hydroxyimino)methyl]-1'H,3H-spiro[2-benzofuran-1,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  [EN] SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS
  [FR] INHIBITEURS DE LA RÉNINE

  摘要：

  肾素抑制剂是螺环哌啶衍生物，其化学式为（I），以及在心血管疾病和肾功能不全治疗中有用的药物组合物。或其立体异构体，或其药用盐，或其药用盐的立体异构体，其中：n，在每次出现时，独立地为0、1或2；W是一个五元或六元饱和或不饱和的杂环或碳环单环，A是（i）一个五元或六元饱和或不饱和的杂环或碳环单环或（ii）一个第一五元或六元饱和或不饱和的杂环或碳环单环，它与第二个五元或六元饱和或不饱和的杂环或碳环单环融合，V是-(C=O)-、-CH2-或=CH-；U是一个键或-CH2-，或者，当V是=CH-时，U是-CH=；X是=CH-、=CF-、=C(OR3)-或-(C=O)-；Y是=CH-、=CF-、=N-，或者，当X为-(C=O)-时，Y是-N(R3)-。

  公开号：

  WO2011057382A1
• 作为产物：
  描述：

  2-溴-4,5-二氟苯甲酸 在 咪唑 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 [(2-bromo-4,5-difluorobenzyl)oxy](tert-butyl)dimethylsilane
  参考文献：
  名称：

  [EN] RENIN INHIBITORS
  [FR] INHIBITEURS DE RÉNINE

  摘要：

  肾素抑制剂是螺环哌啶酰胺，其结构式为（I），以及其药物组合物，用于治疗心血管疾病和肾功能不全。其中n在每次出现时，独立地为0、1或2；R1为氢、C1-6-烷基或C3-6-环烷基，其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代；A为（i）五元或六元饱和或不饱和杂环或碳环单环，或（ii）与另一个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环环；V为键或-(C=O)-、-CH(OH)-、-CH2-或=CH-；U为键或-CH2-，或当V为=CH-时，U为-CH=；X为=CH-、=CF-、=C(OR3)-或-C=O-；Y为=CH-、=CF-、=N-，或当X为-C=O-时，Y为-N(R3)-。

  公开号：

  WO2011020193A1

文献信息

• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2011020193A1

  公开（公告）日：2011-02-24

  Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or C3-6-cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

  肾素抑制剂是螺环哌啶酰胺，其结构式为（I），以及其药物组合物，用于治疗心血管疾病和肾功能不全。其中n在每次出现时，独立地为0、1或2；R1为氢、C1-6-烷基或C3-6-环烷基，其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代；A为（i）五元或六元饱和或不饱和杂环或碳环单环，或（ii）与另一个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环环；V为键或-(C=O)-、-CH(OH)-、-CH2-或=CH-；U为键或-CH2-，或当V为=CH-时，U为-CH=；X为=CH-、=CF-、=C(OR3)-或-C=O-；Y为=CH-、=CF-、=N-，或当X为-C=O-时，Y为-N(R3)-。
• RENIN INHIBITORS
  申请人：Chen Austin Chih-Yu

  公开号：US20120190701A1

  公开（公告）日：2012-07-26

  Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R 1 is hydrogen, C 1-6 -alkyl or C 3-6 -cycloalkyl, wherein said C 1-6 -alkyl or C 3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or —(C═O)—, —CH(OH)—, —CH 2 —or ═CH—; U is a bond or —CH2-, or for the case when V is ═CH—, U is —CH═; X is ═CH—, ═CF—, ═C(OR 3 )—, or —C═O—; and Y is ═CH—, ═CF—, ═N—, or for the case when X is —C═O—, Y is —N(R 3 )—.

  Renin抑制剂是一种螺环吡啶酰胺，其结构式(I)，以及在心血管疾病和肾功能不全治疗中有用的制药组合物。其中n，在每次出现时，独立地为0、1或2；R1是氢、C1-6-烷基或C3-6-环烷基，其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代；A是(i)五元或六元饱和或不饱和杂环或碳环单环，或(ii)与另一个五元或六元饱和或不饱和杂环或碳环融合的五元或六元饱和或不饱和杂环或碳环，V是键或—(C═O)—、—CH(OH)—、—CH2—或═CH—；U是键或—CH2-，或对于V为═CH—的情况，U是—CH═；X是═CH—、═CF—、═C(OR3)—或—C═O—；Y是═CH—、═CF—、═N—，或对于X为—C═O—的情况，Y是—N(R3)—。
• SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS
  申请人：Chen Austin

  公开号：US20120202837A1

  公开（公告）日：2012-08-09

  Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which it occurs, is independently 0, 1, or 2; W is a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring, A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a first five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to a second five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is —(C═O)—, —CH 2 — or ═CH—; U is a bond or —CH2-, or, when V iS ═CH—, U is —CH═; X is ═CH—, ═CF—, ═C(OR 3 )—, or —(C═O)—; and Y is ═CH—, ═CF—, ═N—, or, for the case when X is —(C═O)—, Y is —N(R 3 )—.

  Renin抑制剂是一种螺环哌啶衍生物，其化学式为（I），以及其在心血管疾病和肾功能不全治疗中有用的制药组合物，或其立体异构体，或其药学上可接受的盐，或其立体异构体的药学上可接受的盐，其中：n，在每个出现的情况下，独立地为0、1或2；W为五元或六元饱和或不饱和杂环或碳环单环，A为（i）五元或六元饱和或不饱和杂环或碳环单环，或（ii）第一个与第二个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环单环，V为—（C═O）—、—CH2—或═CH—；U为键或—CH2-，或当V为═CH—时，U为—CH═；X为═CH—、═CF—、═C（OR3）—或—（C═O）—；Y为═CH—、═CF—、═N—，或当X为—（C═O）—时，Y为—N（R3）—。
• [EN] SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2011057382A1

  公开（公告）日：2011-05-19

  Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which it occurs, is independently 0, 1, or 2; W is a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring, A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a first five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to a second five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is -(C=O)-, -CH2- or =CH-; U is a bond or -CH2-, or, when V iS =CH-, U is-CH=; X is =CH-, =CF-, =C(OR3)-, or -(C=O)-; and Y is =CH-, =CF-, =N-, or, for the case when X is -(C=O)-, Y is -N(R3)-.

  肾素抑制剂是螺环哌啶衍生物，其化学式为（I），以及在心血管疾病和肾功能不全治疗中有用的药物组合物。或其立体异构体，或其药用盐，或其药用盐的立体异构体，其中：n，在每次出现时，独立地为0、1或2；W是一个五元或六元饱和或不饱和的杂环或碳环单环，A是（i）一个五元或六元饱和或不饱和的杂环或碳环单环或（ii）一个第一五元或六元饱和或不饱和的杂环或碳环单环，它与第二个五元或六元饱和或不饱和的杂环或碳环单环融合，V是-(C=O)-、-CH2-或=CH-；U是一个键或-CH2-，或者，当V是=CH-时，U是-CH=；X是=CH-、=CF-、=C(OR3)-或-(C=O)-；Y是=CH-、=CF-、=N-，或者，当X为-(C=O)-时，Y是-N(R3)-。
• Renin inhibitors for the treatment of hypertension: Design and optimization of a novel series of spirocyclic piperidines
  作者：Austin Chen、Renee Aspiotis、Louis-Charles Campeau、Elizabeth Cauchon、Amadine Chefson、Yves Ducharme、Jean-Pierre Falgueyret、Sébastien Gagné、Yongxin Han、Robert Houle、Sébastien Laliberté、Guillaume Larouche、Jean-François Lévesque、Dan McKay、David Percival

  DOI：10.1016/j.bmcl.2011.10.013

  日期：2011.12

  The discovery and SAR of a novel series of spirocyclic renin inhibitors are described herein. It was found that by restricting the northern aromatic plate to the bioactive conformation through spirocyclization, increase in renin potency and decrease in hERG affinity could both be realized. When early members of this series were found to be potent time-dependent CYP3A4 inhibitors, two distinct strategies to address this liability were explored and this effort culminated in the identification of compound 31 as an optimized renin inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.